Author’s reply to BlakeBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1347 (Published 08 March 2016) Cite this as: BMJ 2016;352:i1347
- Ian C K Wong, professor
- Research Department of Practice and Policy, UCL School of Pharmacy, London WC1N 1AX, UK
We attempted to use three study designs to investigate the association between clarithromycin and cardiovascular outcomes in two cohorts of patients.1 2 The first was a propensity score adjusted cohort design comparing exposure to clarithromycin with exposure to amoxicillin or amoxicillin plus clavulanate potassium. The second was a self controlled case series design comparing the rate of cardiovascular events after exposure to Helicobacter pylori therapy containing clarithromycin with baseline of follow-up. The third study design was a case crossover study design comparing odds of exposure to H pylori therapy containing clarithromycin in 14 days before a cardiovascular event with the odds of exposure during control periods. The last two designs are both case-only designs using the same cohort, but the designs are very different.3 4 …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial